Leerink Partners Initiates Coverage On Seaport Therapeutics with Outperform Rating, Announces Price Target of $35
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Leerink Partners analyst Marc Goodman initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Outperform rating and announces Price Target of $35.
Leerink Partners analyst Marc Goodman initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Outperform rating and announces Price Target of $35.